Browse
Submit Data
Databases
API
Help

Dataset Information

7 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A feasibility study of capecitabine and oxaliplatin (XELOX) for patients with stage II/III colon cancer.

ABSTRACT: Interventions: XELOX Capecitabine:2000mg/m2 d1-14 Oxaliplatin:130mg/m2 d1 Q3w Primary outcome(s): Completion rate of treatment Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2623439 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Prospective cohort study of optimal discontinuation of oxaliplatin in elderly patients treated with XELOX plus bevacizumab

Project description:Interventions: XELOX+BEV Capecitabine:2000mg/m2 d1-14 Oxaliplatin:130mg/m2 d1 Bevacizumab:7.5mg/kg d1 Q3w Discontinuation of oxaliplatin when neurotoxicity develops >=Grade2 Primary outcome(s): Rate of Grade3 neuropathy Study Design: Single arm Non-randomized

| 2631347 | ecrin-mdr-crc

A non-inferiority study of apatinib versus bevacizumab combined with XELOX regimen in the treatment of metastatic colorectal cancer

Project description:Interventions: Experimental group:Apatinib 250mg po, qd, continuous taken; XELOX: Oxaliplatin 135 mg/m2 Ivgtt d1, Capecitabine 1000mg/m2 d1-14, q3w;Control group:Bevacizumab 7.5mg/kg, q3w; XELOX: Oxaliplatin 135 mg/m2 Ivgtt d1, Capecitabine 1000mg/m2 d1-14, q3w Primary outcome(s): Progress-free survival (PFS) Study Design: Non randomized control

| 2687981 | ecrin-mdr-crc

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Project description:In this open-label phase III study, patients with local advanced colon cancer (TanyN+ ,M0, dMMR/MSI-H, at least 10cm from the anus verge)will be scheduled to Group A: receive anti-PD-1 antibody alone (8 cycles, 200mg iv drip Q3W) and Group B (4 or 8 cycles of XELOX: oxaliplatin 130mg/m2 day 1, capecitabine 2000mg/m2 days 1-14, repeated every 21 days). The primary endpoint was 3 Disease-free survival; analyses were done based on all patients with post-randomization data.

| 2404460 | ecrin-mdr-crc

Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine, irinotecan plus bevacizmab for metastatic colorectal cancer

Project description:Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Oxaliplatin 130mg/m2 day1 Capecitabin 2000mg/m2/day day1-15 Primary outcome(s): ORR;Over response rate Study Design: Single arm Non-randomized

| 2626922 | ecrin-mdr-crc

Feasibility study of adjuvant chemotherapy with FOLFOX(or XELOX) for 3 months followed by oral anticancer drug for 3 months in patients with completely resected colorectal cancer

Project description:Interventions: mFOLFOX6 therapy(or XELOX therapy) for 3 months followed by capecitabine for 3 months mFOLFOX6 therapy Day1 L-OHP 85mg/m2,l-LV 200mg/m2 Day1 bolus 5FU 400mg/m2 Day1~2 Infusional 5FU 2400mg/m2 XELOX therapy Day1 L-OHP 130mg/m2 Day1~14(b.i.d. at the end of meal) capecitabine 2000mg/m2/day Capecitabine therapy Day1~14(b.i.d. at the end of meal) Capecitabine 2500mg/m2/day Primary outcome(s): Frequency and Grade of peripheral neuropathy(CTCAE v4 and PNQ) Study Design: Single arm Non-randomized

| 2620377 | ecrin-mdr-crc

A Randomized, Controlled, Multicenter Clinical Trial of Kangai Injection in Combination with Chemotherapy XELOX in Treatment of Colorectal Cancer

Project description:Interventions: Experiment group:Kangai injection 60ml ivgtt D1-14 Q21d, combined with chemotherapy: Eloxatin 130mg/m2 2h ivgtt d1, Xeloda 1000mg/m2 bid po d1-14 Q21d;Control group:Chemotherapy: Eloxatin 130mg/m2 2h ivgtt d1, Xeloda 1000mg/m2 bid po d1-14 Q21d Primary outcome(s): Adverse Reactions Study Design: Randomized parallel controlled trial

| 2674808 | ecrin-mdr-crc

Clinical efficacy and biomarker assessment of Capecitabine plus oxaliplatin (XELOX) in combination with Bevacizumab as second-line therapy in patients with advanced or recurrent colorectal cancer after failure to irinotecan. Multi-center phase II Study.

Project description:Interventions: Capecitabine plus oxaliplatin (XELOX) in combination with Bevacizumab. Capecitabine:2000mg/m2/day p.o.(day1-15) Oxaliplatin:130mg/m2 i.v.(day1) Bevacizumab:7.5mg/kg i.v.(day1) to be repeated every 3 weeks Primary outcome(s): 6-month Progression free survival rate Study Design: Single arm Non-randomized

| 2620624 | ecrin-mdr-crc

Randomized phase II study of oxaliplatin reintroduction and the biweekly XELOX in previously treated patients with metastatic colorectal cancer (ORION study)

Project description:Interventions: Oxaliplatin 130mg/m2 day1 Capacitabine 2000mg/m2 day1-14 every 3 weeks Oxaliplatin 85mg/m2 day1 Capacitabine 2000mg/m2 day1-7 every 2 weeks Primary outcome(s): time to treatment failure Study Design: Parallel Randomized

| 2619574 | ecrin-mdr-crc

Observational study of XELOX in combination with bevacizumab for advanced or recurrent colorectal cancer

Project description:Interventions: Oxaliplatin 130mg/m2 i.v.(day1) Bevacizumab 7.5mg/kg i.v.(day1) Capecitabine 2000mg/m2 p.o.(day1-14) to be repeated every 3weeks Primary outcome(s): Overall response rate Study Design: Single arm Non-randomized

| 2620414 | ecrin-mdr-crc

Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC

Project description:This is a two-group, parallel, randomized, standard-control phase II study comparing the safety and efficacy of trifluridine/tipiracil combined with oxaliplatin and bevacizumab versus XELOX plus bevacizumab in the first-line treatment of advanced colorectal cancer. This study was conducted in the Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital. Patients with advanced colorectal cancer will be randomly assigned (1:1) to trifluridine/tipiracil combined with oxaliplatin and bevacizumab (experimental group) or XELOX plus bevacizumab (control group) after signing informed consent. In this study, 184 patients will be enrolled, 92 patients will receive trifluridine/tipiracil combined with oxaliplatin and bevacizumab and 92 patients will receive standard therapy. In the experimental group, the treatment regimen is trifluridine/tipiracil 35mg/m2 orally taken on d1-5 and d8-12, oxaliplatin 85mg/m2 and bevacizumab 5mg/kg intravenously infused on d1 and d15 every 4 weeks, up to 6 cycles. Then patients will be given trifluridine/tipiracil and bevacizumab maintenance treatment. Patients enrolled in this group could acquire trifluridine/tipiracil free of charge. The control group was XELOX plus bevacizumab regimen, bevacizumab 7.5mg/kg, d1 oxaliplatin 130mg/m2, d1, capecitabine 1000mg/m2, orally, bid (half an hour after breakfast and dinner), d1-14, every 3 weeks, up to 8 cycles. Then patients will be given capecitabine and bevacizumab maintenance treatment. Patients received regular and periodic reviews, with imaging evaluations every 8 weeks. Safety will be evaluated by AE and laboratory tests. All patients were followed up every 3 months until death according to the plan.

| 2392221 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data